Sulzer Chemtech is supporting Farmhispania Group to increase the production capacity of one of its drugs, which has proven its effectiveness in the treatment of critically ill COVID-19 patients. This will help the pharmaceutical manufacturer to meet rising global healthcare demands for the medicament. The key technology that will help intensify the manufacturing process as quickly as possible is Sulzer’s agitated Kühni column (ECR) for liquid-liquid extraction.
The urgency with which pharma businesses need to meet the rising demands of global healthcare production doesn’t provide sufficient time for them to significantly expand their operations by increasing their manufacturing footprint. For producers of antimalaria drugs, immunosuppressants and HIV medications, the pressure may be even higher, as these medicines are currently among the most promising treatments for the most critically ill coronavirus patients hospitalized in intensive care units.
Pharmaceutical ingredient manufacturer, Farmhispania, has found a way to address these challenges and produce more medicines suitable for coronavirus treatment. By working together with Sulzer, the leader in separation and mixing technology, the business will be able to ramp up its production capabilities in less than two weeks.
The two partners identified Sulzer’s ECR, a high-performance advanced extraction technology, as the most ideal solution. The separation system is particularly suitable for this project, as it can effectively handle a high flow rate, maximizing throughput.
To ensure a prompt delivery to the pharmaceutical manufacturer Sulzer was able to utilize its available stock to build an ECR and ship it over the weekend, the day after the contract was awarded. Furthermore, Sulzer is supporting the equipment installation and start-up, getting production ramped up as quickly as possible.
Dr. Jordi Cervelló Pagès, Industrial Director at Farmhispania Group, comments: “The exceptional circumstances presented by the threat of COVID-19 require pharmaceutical manufacturers to work with great urgency in the interest of the public good. In our case, this means delivering high volumes of one of our drugs as quickly as possible to support the recovery of coronavirus patients in critical conditions in multiple intensive care units. Sulzer’s role is crucial, as its technology and comprehensive service will enable us to significantly expand our operations in a very short time.”
Torsten Wintergerste, Division President for Sulzer Chemtech, concludes: “We couldn’t be prouder to help Farmhispania and personally, I am extremely grateful to our Sulzer staff that quickly mobilized to deliver the ECR within days. As soon as our teams realized that the project would support the fight against coronavirus, they immediately showed their commitment to go the extra mile, even if this meant working during the weekend. Sulzer has the capabilities to support pharmaceutical businesses in these challenging times, so we invite businesses interested in similar situations to get in touch with us to discuss how we can help them.”
Sulzer is a global leader in fluid engineering. We specialize in pumping, agitation, mixing, separation and application technologies for fluids of all types. Our customers benefit from our commitment to innovation, performance and quality and from our responsive network of 180 world-class manufacturing facilities and service centers across the globe. Sulzer has been headquartered in Winterthur, Switzerland, since 1834. In 2019, our 16’500 employees delivered revenues of CHF 3.7 billion. Our shares are traded on the SIX Swiss Exchange (SIX: SUN).
The Chemtech division is the global market leader in innovative mass transfer, static mixing and polymer solutions for petrochemicals, refining, LNG, biopolymers and biofuels. Our product offering ranges from process components to complete separation process plants, including licensing. Customer support covers engineering services and field services to tray and packing installation, tower maintenance, welding and plant turnaround projects.
We are inviting Individual Blogger | News Publications | Professionals | Brands | Citizens | Kids | Youth | Social Workers to
Contact/WhatsApp: +91 7827887720 Email: email@example.com
Disclaimer: The perspectives communicated in the article/news/press release above are those of the writers’ and don’t really speak to or mirror the perspectives of this website or its personnel. Except if in any case noticed, the writer is writing in his/her own ability. They are not expected and ought not to be thought to speak to legitimate thoughts, perspectives, or strategies of any individual, Institution, organization or foundation.